Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Harvard Business School
Johnson and Johnson
McKinsey
Boehringer Ingelheim

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Tasimelteon - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for tasimelteon and what is the scope of freedom to operate?

Tasimelteon is the generic ingredient in one branded drug marketed by Vanda Pharms Inc and is included in one NDA. There are ten patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tasimelteon has one hundred and twenty-three patent family members in thirty-one countries.

There are three drug master file entries for tasimelteon. One supplier is listed for this compound.

Recent Clinical Trials for tasimelteon

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Saint-Joseph UniversityPhase 3
Vanda PharmaceuticalsPhase 2
Vanda PharmaceuticalsPhase 4

See all tasimelteon clinical trials

Recent Litigation for tasimelteon

Identify potential future generic entrants

District Court Litigation
Case NameDate
Vanda Pharmaceuticals Inc. v. MSN Pharmaceuticals Inc.2019-05-17
Vanda Pharmaceuticals Inc. v. Apotex Inc.2019-04-12
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.2019-03-22

See all tasimelteon litigation

Pharmacology for tasimelteon
Synonyms for tasimelteon
(-)-(trans)-N-[[2-(2,3-Dihydrobenzofuran-4-yl)cycloprop-1-yl] methyl]propanamide
(trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl) cyclopropyl]methyl]propanamide
(trans)-N-[[2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl]methyl]propanamide
209255-28-7
609799-22-6
799T226
AC-6143
ACT06729
AK188029
AKOS025149360
AN-10364
AS-35291
BCP07180
BMS 214778
BMS-214778
CHEBI:79042
CHEMBL2103822
CS-5512
D09388
DB09071
DTXSID70209826
EX-A2729
GTPL7393
Hetlioz
Hetlioz (TN)
HY-14803
J3.640.465E
KS-0000063S
MolPort-028-600-027
N-(((1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl)methyl)propanamide
N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide
N-([(1r,2r)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide
N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide
N-[[(1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl]methyl]propanamide
N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide
Propanamide, N-(((1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl)methyl)-
PTOIAAWZLUQTIO-GXFFZTMASA-N
SB16782
SCHEMBL3505912
SHS4PU80D9
Tasimelteon (USAN/INN)
Tasimelteon [USAN:INN]
Tasimelteon, >=98% (HPLC)
tasimelteonum
UNII-SHS4PU80D9
VEC 162
VEC-162
X5820
ZINC4392649
Paragraph IV (Patent) Challenges for TASIMELTEON
Tradename Dosage Ingredient NDA Submissiondate
HETLIOZ CAPSULE;ORAL tasimelteon 205677 2018-01-31

US Patents and Regulatory Information for tasimelteon

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.